{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:07:49Z","timestamp":1787843269378,"version":"build-2784847793"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejca.2023.113336","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T05:36:55Z","timestamp":1694237815000},"page":"113336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial"],"prefix":"10.1016","volume":"194","author":[{"given":"Shan-Shan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Song","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Chong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Lan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Fei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-3648","authenticated-orcid":false,"given":"Ji-Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Yuan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Dong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Quan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Qiang","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113336_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.113336_bib2","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1200\/JCO.2008.19.9109","article-title":"Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225","volume":"27","author":"Lee","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113336_bib3","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113336_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.oraloncology.2017.12.004","article-title":"Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: a report of 3328 patients (HKNPCSG 1301 study)","volume":"77","author":"Au","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2023.113336_bib5","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1200\/JCO.2002.07.011","article-title":"Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation","volume":"20","author":"Rischin","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113336_bib6","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.7150\/jca.33303","article-title":"Safety and effectiveness of de-escalated radiation dose in T1-3 nasopharyngeal carcinoma: a propensity matched analysis","volume":"10","author":"Wang","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.ejca.2023.113336_bib7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.oraloncology.2014.01.017","article-title":"The impact of dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRT","volume":"50","author":"Ng","year":"2014","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2023.113336_bib8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1470-2045(17)30246-2","article-title":"Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study","volume":"18","author":"Chen","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113336_bib9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.2016.68.3300","article-title":"E1308: phase ii trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN cancer research group","volume":"35","author":"Marur","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113336_bib10","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/(SICI)1097-0142(19970901)80:5<951::AID-CNCR18>3.0.CO;2-V","article-title":"Nasopharyngeal carcinoma in childhood and adolescence: concept and preliminary results of the cooperative GPOH study NPC-91. Gesellschaft f\u00fcr P\u00e4diatrische Onkologie und H\u00e4matologie","volume":"80","author":"Mertens","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.113336_bib11","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/cncr.21258","article-title":"Treatment of nasopharyngeal carcinoma in children and adolescents: definitive results of a multicenter study (NPC-91-GPOH)","volume":"104","author":"Mertens","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.113336_bib12","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/cncr.26528","article-title":"A prospective protocol for nasopharyngeal carcinoma in children and adolescents: the Italian Rare Tumors in Pediatric Age (TREP) project","volume":"118","author":"Casanova","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.113336_bib13","first-page":"1163","article-title":"Deintensified chemoradiotherapy for pretreatment Epstein-Barr\u00a0virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma: a phase II randomized non-inferiority","volume":"40","author":"Li","year":"2022","journal-title":"Trial"},{"key":"10.1016\/j.ejca.2023.113336_bib14","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2016"},{"key":"10.1016\/j.ejca.2023.113336_bib15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1186\/s12885-018-5192-x","article-title":"Liposomal paclitaxel versus docetaxel in induction chemotherapy using taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma","volume":"18","author":"Liu","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.113336_bib16","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1080\/14656566.2016.1204293","article-title":"A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation\/surgery","volume":"17","author":"Wang","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ejca.2023.113336_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.5732\/cjc.012.10095","article-title":"Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation","volume":"31","author":"Li","year":"2012","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.ejca.2023.113336_bib18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.radonc.2013.10.010","article-title":"Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines","volume":"110","author":"Gr\u00e9goire","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2023.113336_bib19","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijrobp.2008.11.059","article-title":"Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer","volume":"75","author":"Salama","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2023.113336_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113336_bib21","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/cncr.20099","article-title":"Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A\/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma","volume":"100","author":"Shao","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.113336_bib22","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2023.113336_bib23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(18)30104-9","article-title":"Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial","volume":"19","author":"Tang","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113336_bib24","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/sim.6394","article-title":"Sample size calculation for the one-sample log-rank test","volume":"34","author":"Schmidt","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2023.113336_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/pst.1654","article-title":"Sample size calculation for the one-sample log-rank test","volume":"14","author":"Wu","year":"2015","journal-title":"Pharm Stat"},{"key":"10.1016\/j.ejca.2023.113336_bib26","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113336_bib27","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2015.08.003","article-title":"The prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma","volume":"93","author":"Liu","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2023.113336_bib28","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","article-title":"Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma","volume":"27","author":"Hui","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113336_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.oraloncology.2015.11.015","article-title":"Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma","volume":"53","author":"Setton","year":"2016","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2023.113336_bib30","doi-asserted-by":"crossref","first-page":"873","DOI":"10.6004\/jnccn.2020.0031","article-title":"Head and neck cancers, version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Pfister","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2023.113336_bib31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijrobp.2007.02.032","article-title":"Nasopharyngeal cancers: which method should be used to measure these irregularly shaped tumors on cross-sectional imaging?","volume":"69","author":"King","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2023.113336_bib32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300638X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300638X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:40:12Z","timestamp":1716392412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492300638X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":32,"alternative-id":["S095980492300638X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113336","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113336"}}